- Home
- TNDM vs CVAC Comparison
TNDM vs CVAC Comparison
Compare TNDM & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNDM
- CVAC
- Stock Information
- Founded
- TNDM 2006
- CVAC 2000
- Country
- TNDM United States
- CVAC Germany
- Employees
- TNDM N/A
- CVAC N/A
- Industry
- TNDM Medical/Dental Instruments
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- TNDM Health Care
- CVAC Health Care
- Exchange
- TNDM Nasdaq
- CVAC Nasdaq
- Market Cap
- TNDM 1.1B
- CVAC 1.2B
- IPO Year
- TNDM 2013
- CVAC 2020
- Fundamental
- Price
- TNDM $15.50
- CVAC $5.37
- Analyst Decision
- TNDM Buy
- CVAC Hold
- Analyst Count
- TNDM 16
- CVAC 3
- Target Price
- TNDM $23.25
- CVAC $6.83
- AVG Volume (30 Days)
- TNDM 1.9M
- CVAC 420.0K
- Earning Date
- TNDM 11-06-2025
- CVAC 11-11-2025
- Dividend Yield
- TNDM N/A
- CVAC N/A
- EPS Growth
- TNDM N/A
- CVAC N/A
- EPS
- TNDM N/A
- CVAC 1.01
- Revenue
- TNDM $1,001,719,000.00
- CVAC $599,540,810.00
- Revenue This Year
- TNDM $8.27
- CVAC N/A
- Revenue Next Year
- TNDM $9.72
- CVAC $23.83
- P/E Ratio
- TNDM N/A
- CVAC $5.33
- Revenue Growth
- TNDM 25.84
- CVAC 675.15
- 52 Week Low
- TNDM $9.98
- CVAC $2.37
- 52 Week High
- TNDM $38.28
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- TNDM 62.48
- CVAC 46.64
- Support Level
- TNDM $14.53
- CVAC $5.34
- Resistance Level
- TNDM $15.57
- CVAC $5.41
- Average True Range (ATR)
- TNDM 0.86
- CVAC 0.03
- MACD
- TNDM 0.14
- CVAC -0.00
- Stochastic Oscillator
- TNDM 92.45
- CVAC 22.73
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.